Provectus Pharmaceuticals Inc. Receives US Patent Providing Further Protection for Novel Agent PH-12

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has received its third US patent protecting novel therapeutic agents and methods from the United States Patent and Trademark Office (USPTO). The current patent covers radiosensitizer agents based on PH-12, the Company’s novel analog of PV-10 and PH-10, designed to enhance effectiveness of radiation therapy.

Back to news